Mostrar o rexistro simple do ítem

dc.contributor.authorFuentes, Manuel
dc.contributor.authorRuiz-Romero, Cristina
dc.contributor.authorMisiego, Sara
dc.contributor.authorJuanes-Velasco, Pablo
dc.contributor.authorLandeira-Viñuela, Alicia
dc.contributor.authorTorres-Roda, Adrián
dc.contributor.authorLorenzo-Gil, Héctor
dc.contributor.authorGonzález-González, María
dc.contributor.authorHernández, Ángela P.
dc.contributor.authorLourido, Lucía
dc.contributor.authorSjöberg, Ronald
dc.contributor.authorPin, Elisa
dc.contributor.authorLas Rivas, Javier de
dc.contributor.authorSánchez-Santos, José Manuel
dc.contributor.authorNilsson, Peter
dc.contributor.authorBlanco García, Francisco J
dc.date.accessioned2023-02-09T09:10:01Z
dc.date.issued2022-12-07
dc.identifier.citationFuentes M, Ruiz-Romero C, Misiego S, Juanes-Velasco P, Landeira-Viñuela A, Torres-Roda A, Lorenzo-Gil H, González-González M, Hernández ÁP, Lourido L, Sjöberg R, Pin E, de Las Rivas J, Sánchez-Santos JM, Nilsson P, Blanco FJ. Exploring High-Throughput Immunoassays for Biomarker Validation in Rheumatic Diseases in the Context of the Human Proteome Project. J Proteome Res. 2023 Apr 7;22(4):1105-1115.es_ES
dc.identifier.issn1535-3893
dc.identifier.urihttp://hdl.handle.net/2183/32458
dc.description.abstract[Abstract] Rheumatic diseases are high prevalence pathologies with different etiology and evolution and low sensitivity in clinical diagnosis. Therefore, it is necessary to develop an early diagnosis method which allows personalized treatment, depending on the specific pathology. The biology/disease initiative, at Human Proteome Project, is an integrative approach to identify relevant proteins in the human proteome associated with pathologies. A previously reported literature data mining analysis, which identified proteins related to osteoarthritis (OA), rheumatoid arthritis (RA), and psoriatic arthritis (PSA) was used to establish a systematic prioritization of potential biomarkers candidates for further evaluation by functional proteomics studies. The aim was to study the protein profile of serum samples from patients with rheumatic diseases such as OA, RA, and PSA. To achieve this goal, customized antibody microarrays (containing 151 antibodies targeting 121 specific proteins) were used to identify biomarkers related to early and specific diagnosis in a screening of 960 serum samples (nondepleted) (OA, n = 480; RA, n = 192; PSA, n = 288). This functional proteomics screening has allowed the determination of a panel (30 serum proteins) as potential biomarkers for these rheumatic diseases, displaying receiver operating characteristics curves with area under the curve values of 80-90%.es_ES
dc.description.sponsorshipWe gratefully acknowledge financial support from the Spanish Health Institute Carlos III (ISCIII) for the grants FIS PI21/01545, PI19/01206, PI20/00793, CB16/12/00400, and CB06/01/0040. We also acknowledge Fondos FEDER (EU) and Junta Castilla-León (COVID-19 grant COV20EDU/00187). The Proteomics Units belong to ProteoRed, PRB3-ISCIII, supported by grants PT17/0019/0023 and PT17/0019/0014 of the PE I+D+I 2017-2020, funded by ISCIII and FEDER. This research work was funded by the European Commission – NextGeneration EU, through CSIC’s Global Health Platform (PTI+ Salud Global). This work was performed in the framework of NanoMedicine CSIC HUB (ref 202180E048). P.J.-V. is supported by JCYL PhD Program “Nos Impulsa-JCYL” and scholarship JCYL-EDU/601/2020. A.L.-V. is supported by VIII Centenario-USAL PhD Program. L.L. is supported by a Sara Borrell contract (CD19/00229)es_ES
dc.description.sponsorshipinfo:eu-repo/grantAgreement/ISCIII/Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I/PI19%2F01206/ES/VALIDACION CLINICA DE NUEVOS BIOMARCADORES PREDICTIVOS DE DIAGNOSTICO Y PRONOSTICO EN ARTROSIS: EL PROYECTO HPPes_ES
dc.description.sponsorshipinfo:eu-repo/grantAgreement/ISCIII/Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I/PI20%2F00793/ES/DESARROLLO DE SOLUCIONES INTEGRADAS DE ANALITICA PREDICTIVA PARA PERSONALIZAR LA FARMACOTERAPIA EN PACIENTES CON ARTRITIS REUMATOIDEes_ES
dc.description.sponsorshipinfo:eu-repo/grantAgreement/MINECO/Programa Estatal de I+D+I Orientada a los Retos de la Sociedad/CB16%2F12%2F00400/ES/CANCERes_ES
dc.description.sponsorshipInstituto de Salud Carlos III; CB06/01/0040es_ES
dc.description.sponsorshipJunta de Castilla y León; COV20EDU/00187es_ES
dc.description.sponsorshipinfo:eu-repo/grantAgreement/ISCIII/Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I/PI21%2F01545/ES/CARACTERIZACION SISTEMATICA MEDIANTE PROTEOMICA FUNCIONAL DE LA DISFUNCION DE LA RESPUESTA INMUNE EN HEMOPATIAS MALIGNAS, SIENDO LA LEUCEMIA LINFOIDE CRÓNICA (LLC) COMO MODELO.
dc.language.isoenges_ES
dc.publisherACS Publicationses_ES
dc.relation.urihttps://doi.org/10.1021/acs.jproteome.2c00387es_ES
dc.rightsThis document is the Accepted Manuscript version of a Published Work that appeared in final form in Journal of Proteomic Research, after peer review and technical editing by the publisher. To access the final edited and published work see ACSPublications web page.es_ES
dc.subjectHuman Proteome Projectes_ES
dc.subjectBiomarkerses_ES
dc.subjectOsteoarthritises_ES
dc.subjectProtein microarrayses_ES
dc.subjectPsoriatic arthritises_ES
dc.subjectRheumatoid arthritises_ES
dc.titleExploring high-throughput immunoassays for biomarker validation in rheumatic diseases in the context of the human proteome projectes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/embargoedAccesses_ES
dc.date.embargoEndDate2023-12-07es_ES
dc.date.embargoLift2023-12-07
UDC.journalTitleJournal of Proteome Researches_ES


Ficheiros no ítem

Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem